GAMP 5 and AI: A Practical Guide to Validating Intelligent Systems

GAMP 5 (Good Automated Manufacturing Practice) has been the gold standard for computer system validation in pharmaceutical manufacturing for 20+ years. It's how the industry validates ERP systems, QMS platforms, LIMS, MES, and every other piece of software that touches GxP processes.

But GAMP 5 was written for deterministic software — systems that produce the same output for the same input, every time.

AI/ML systems don't work that way. They're probabilistic, adaptive, and non-deterministic. And that creates a validation challenge.

Here's the uncomfortable truth: most pharmaceutical companies are validating AI systems using GAMP 5 frameworks that weren't designed for AI — and creating compliance risk in the process.

This guide provides a practical, risk-based approach to AI validation that satisfies regulatory expectations while actually being operationally feasible.

Why Traditional GAMP 5 Categories Don't Fit AI

GAMP 5 classifies software into categories based on complexity and risk:

The problem: AI/ML systems don't fit cleanly into any of these categories.

Why AI Breaks the GAMP 5 Model

1. AI isn't deterministic

2. AI behavior changes over time

3. AI outputs aren't fully explainable

4. AI validation requires different testing approaches

Translation: If you try to force AI into GAMP 5 Category 4 or 5 and validate it like traditional software, you'll either:

The Proposed AI Classification: Extending GAMP 5

Here's a pragmatic AI classification framework that pharmaceutical companies are using (aligned with GAMP 5 principles but adapted for AI):

AI Category A: Deterministic Rule-Based Systems (Low Complexity)

Description: "AI" systems that use fixed, human-defined rules with no machine learning

Examples:

Validation approach: Treat like GAMP 5 Category 4 (configured product)

Key point: These aren't really "AI" in the modern sense — they're configurable logic engines. Standard GAMP 5 validation works fine.

AI Category B: Fixed ML Models (Medium Complexity)

Description: Machine learning models that are trained once, then deployed in a fixed state (no continuous learning)

Examples:

Validation approach: Risk-based validation with AI-specific testing

Key point: This is where most pharmaceutical AI lives today. The model is static between retraining cycles. Validation focuses on demonstrating fitness-for-use at the time of deployment.

AI Category C: Continuously Learning Models (High Complexity)

Description: AI systems that update their behavior based on new data without explicit retraining or revalidation

Examples:

Validation approach: Highest rigor + continuous monitoring

Key point: Most pharmaceutical companies avoid Category C AI in GxP-critical applications because maintaining validation is extremely challenging. If you're considering it, expect intense regulatory scrutiny.

Risk-Based Validation: Match Rigor to Impact

Not every AI system needs the same validation rigor. Use a risk-based approach aligned with ICH Q9.

Validation Rigor by GxP Impact

High-Risk AI (Directly affects patient safety, product quality, or regulatory submissions)

Medium-Risk AI (Supports GxP decisions but doesn't make them autonomously)

Low-Risk AI (No GxP impact, used for efficiency or convenience)

Key insight: Don't waste validation effort on low-risk AI. Save rigor for high-risk applications where validation actually mitigates regulatory and quality risk.

The AI Validation Protocol: What It Actually Looks Like

Here's what a practical AI validation protocol includes (for a Category B, Medium-High Risk AI):

1. System Description and Intended Use

Document:

Example: > "This AI system classifies incoming deviation reports as major or minor based on regulatory seriousness criteria. It suggests classification to QA reviewers, who retain final decision authority. Intended users: QA associates and managers (trained per SOP-QA-015). GxP risk: Medium (influences quality decisions but does not make them autonomously)."

2. Training Data Qualification

Document:

Example: > "Training dataset: 5,847 historical deviation reports from 2021-2025, extracted from Trackwise QMS (validated system). Data quality: 98.7% complete (72 records excluded due to missing seriousness classification). Representativeness: Training data includes all product types and deviation categories. Bias assessment: No significant underrepresentation of any deviation category (chi-square test, p=0.23)."

3. Model Development and Architecture

Document:

Example: > "Model type: Random forest classifier (100 trees, max depth 10). Features: Deviation description text (TF-IDF embeddings), product type, process area, historical recurrence patterns. Development: 80/20 train-test split with 5-fold cross-validation. Training set performance: 92.3% accuracy, 89.7% precision, 90.1% recall."

4. Validation Testing (The Critical Part)

Test on independent test dataset:

Performance metrics:

Subgroup analysis:

Acceptance criteria:

Example test results: > "Test set: 587 deviation reports (not included in training data). Overall accuracy: 91.2%. Precision: 87.4%. Recall: 88.9%. Confusion matrix: [show 2x2 table]. Subgroup analysis: Accuracy ranges from 88.1% (documentation deviations) to 93.7% (equipment deviations). All subgroups meet acceptance criteria (≥85%)."

5. Explainability and Limitations

Document:

Example: > "The AI classifies deviations based on keyword patterns, historical similarity, and regulatory seriousness indicators. Known limitations: AI struggles with ambiguous descriptions (accuracy drops to 78% when description is <50 words). AI does not assess regulatory reportability (this requires human judgment). Users should override AI when: (1) deviation involves novel product or process, (2) description is ambiguous or incomplete, (3) regulatory context has changed since training data."

6. Human Oversight and Audit Trail

Document:

Example: > "Workflow: AI analyzes deviation report and suggests classification (major/minor) with confidence score. QA reviewer sees AI suggestion, reviews deviation details, makes final classification decision, and records it in QMS. QA reviewer can override AI at any time. Audit trail: QMS captures AI suggestion, QA reviewer ID, final classification, timestamp, and override rationale (if applicable)."

7. Post-Deployment Monitoring and Revalidation Triggers

Document:

Example: > "Performance monitoring: QA supervisor reviews AI performance monthly (accuracy, precision, recall, override rate). Revalidation triggers: (1) Accuracy drops below 85% for 2 consecutive months, (2) Model is retrained on new data, (3) New deviation categories are added, (4) FDA or EMA guidance changes affect deviation classification criteria."

The "Non-Deterministic Output" Challenge

Here's the hardest validation question for AI: "How do you validate a system that doesn't produce the same output every time?"

Why This Matters

Traditional GAMP 5 validation assumes: If you run the same test twice, you should get the same result.

But some AI systems (especially generative AI like LLMs) are non-deterministic:

Example:

Both outputs are correct. But they're not identical.

How to Validate Non-Deterministic AI

Option 1: Test for Semantic Equivalence (Not Exact Match)

Option 2: Constrain the AI to Reduce Variability

Option 3: Focus Validation on Decision Correctness (Not Output Text)

Bottom line: Non-deterministic AI requires validation approaches that assess correctness and usefulness — not exact reproducibility.

Change Control for AI: When Models Update

One of the trickiest aspects of AI validation: What happens when you retrain the model?

Traditional software: Code changes trigger change control. New version → revalidation (or change impact assessment).

AI systems: Model retraining happens regularly (monthly, quarterly, annually) as new data becomes available. Do you need full revalidation every time?

The Pragmatic Answer: Risk-Based Change Control

Minor model updates (no revalidation required):

Change control: Document retraining, test on holdout dataset, verify performance is maintained, update version control, communicate to users.

Major model updates (revalidation required):

Change control: Full validation impact assessment. If impact is significant → revalidation protocol.

The key: Define upfront (in your validation protocol) what constitutes a "minor" vs. "major" change. This gives you a clear path for ongoing model maintenance without re-validating from scratch every time.

The FDA/EMA Perspective: What Inspectors Are Looking For

FDA and EMA inspectors are asking about AI. Here's what they want to see:

1. "How do you know the AI works?"

What they're really asking: Show me your validation evidence.

What satisfies them:

2. "How do you know the AI is still working?"

What they're really asking: Show me your post-deployment monitoring.

What satisfies them:

3. "What happens when the AI makes a mistake?"

What they're really asking: Show me your risk mitigation and human oversight.

What satisfies them:

4. "Can you explain how the AI reached this decision?"

What they're really asking: Show me explainability and audit trail.

What satisfies them:

The USDM + [GxP Agents Validation Approach](/domains/quality)

USDM Life Sciences has been validating AI systems for pharmaceutical and biotech companies since 2020. We've led:

Our approach: 1. Risk-based validation — match validation rigor to GxP impact (don't over-validate low-risk AI) 2. AI-specific testing — bias testing, robustness testing, subgroup analysis (not just overall accuracy) 3. Practical acceptance criteria — define performance thresholds that balance regulatory risk with operational feasibility 4. Human-in-the-loop by design — no autonomous GxP decisions; AI assists, humans decide 5. Ongoing monitoring — periodic performance review with defined revalidation triggers

And every agent in the [GxP Agents platform](/domains/quality) comes with validation packages designed for pharmaceutical use:

When you deploy a GxP Agent, you're not starting validation from scratch. You're starting with 80% of the validation work already done.

Start Here

If you're validating AI for GxP use, start with three questions:

1. What GxP process does this AI support, and what's the risk if it's wrong? (This determines validation rigor.)

2. Can you demonstrate the AI performs as intended across representative data? (This is the core of validation — show it works, show its limitations.)

3. Do you have human oversight and audit trails in place? (This is what regulators will ask about first.)

The companies that validate AI using risk-based, AI-aware frameworks in 2026 will have a structural advantage: faster deployment, regulatory defensibility, and operational AI that actually works.

The companies that try to force AI into traditional GAMP 5 Category 4 validation will waste time, create gaps, and struggle when inspectors ask the hard questions.

Ready to validate your AI systems the right way? Let's talk about how USDM's [validation practice](/domains/quality) and [GxP Agents' pre-validated AI platform](/domains/quality) can help you deploy AI in GxP environments with confidence — and without starting from scratch.

Download our free resource: [GAMP 5 AI Validation Guide](/resources/gamp-5-ai-validation-guide) — a practical template for validating AI/ML systems in pharmaceutical manufacturing and quality.